Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUST: Methotrexate in Ustekinumab Treatment in PsA
NCT03148860Phase 3Completed
- Sponsor
- Dr. Frank Behrens
- Start
- Dec 2016
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in psoriatic arthritis (PsA) (4 arms), sponsored by Dr. Frank Behrens. Primary endpoint: Disease Activity Score 28 at 24 weeks. Started Dec 2016; status: completed.
02
Drugs
ustekinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03148860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148860.